期刊
ANNALS OF THORACIC SURGERY
卷 98, 期 5, 页码 1865-1874出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.athoracsur.2014.05.006
关键词
-
资金
- Edwards Lifesciences
- Medtronic
- Sorin Group
- St Jude Medical
This article summarizes the long-term clinical results of the Food and Drug Administration-approved heart valves, provides current updates to the objective performance criteria (OPC) used to evaluate new heart valve prostheses, and documents the steps that the International Organization for Standardization Committee used to arrive at the updated OPC. Data were extracted from 19 Food and Drug Administration summaries of safety and effectiveness data reports (31 series) and 56 literature articles (85 series) published from 1999 to 2012. The OPC were calculated for five valve-related complications by valve type (mechanical and bioprosthetic) and valve position (aortic and mitral). (C) 2014 by The Society of Thoracic Surgeons
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据